CL2020002821A1 - Piridazinonas como inhibidoras de parp7. - Google Patents

Piridazinonas como inhibidoras de parp7.

Info

Publication number
CL2020002821A1
CL2020002821A1 CL2020002821A CL2020002821A CL2020002821A1 CL 2020002821 A1 CL2020002821 A1 CL 2020002821A1 CL 2020002821 A CL2020002821 A CL 2020002821A CL 2020002821 A CL2020002821 A CL 2020002821A CL 2020002821 A1 CL2020002821 A1 CL 2020002821A1
Authority
CL
Chile
Prior art keywords
pyridazinones
parp7
inhibitors
parp7 inhibitors
cancer
Prior art date
Application number
CL2020002821A
Other languages
English (en)
Inventor
Melissa Marie Vasbinder
Laurie B Schenkel
Kerren Kalai Swinger
Kevin Wayne Kuntz
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of CL2020002821A1 publication Critical patent/CL2020002821A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con piridazinonas y compuestos relacionados que son inhibidores de PARP7 y son útiles en el tratamiento de cáncer.
CL2020002821A 2018-04-30 2020-10-29 Piridazinonas como inhibidoras de parp7. CL2020002821A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
CL2020002821A1 true CL2020002821A1 (es) 2021-02-19

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002821A CL2020002821A1 (es) 2018-04-30 2020-10-29 Piridazinonas como inhibidoras de parp7.

Country Status (36)

Country Link
US (6) US10550105B2 (es)
EP (2) EP4234551A3 (es)
JP (2) JP6942896B2 (es)
KR (1) KR102862474B1 (es)
CN (2) CN112424188B (es)
AR (1) AR121419A1 (es)
AU (2) AU2019262927B2 (es)
BR (1) BR112020022006A2 (es)
CA (1) CA3098585A1 (es)
CL (1) CL2020002821A1 (es)
CO (1) CO2020013599A2 (es)
CR (1) CR20200518A (es)
CY (1) CY1126132T1 (es)
DK (1) DK3788040T3 (es)
EA (1) EA202092590A1 (es)
EC (1) ECSP20069404A (es)
ES (1) ES2949538T3 (es)
FI (1) FI3788040T3 (es)
HR (1) HRP20230458T1 (es)
HU (1) HUE062096T2 (es)
IL (2) IL308983B2 (es)
LT (1) LT3788040T (es)
MA (1) MA52486B1 (es)
MD (1) MD3788040T2 (es)
MX (2) MX2020011465A (es)
PE (1) PE20211382A1 (es)
PH (1) PH12020551760A1 (es)
PL (1) PL3788040T3 (es)
PT (1) PT3788040T (es)
RS (1) RS64283B1 (es)
SG (1) SG11202010183XA (es)
SI (1) SI3788040T1 (es)
SM (1) SMT202300172T1 (es)
TW (2) TWI877697B (es)
WO (1) WO2019212937A1 (es)
ZA (1) ZA202006549B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212946A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Screening methods for parp modulators
EA202092590A1 (ru) * 2018-04-30 2021-04-08 Рибон Терапьютикс Инк. Пиридазиноны в качестве ингибиторов parp7
WO2019241131A1 (en) 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
EP3846806A4 (en) 2018-09-04 2022-06-08 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
WO2020191056A1 (en) * 2019-03-20 2020-09-24 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN121378271A (zh) * 2019-10-07 2026-01-23 康蒂内乌姆医疗公司 毒蕈碱型乙酰胆碱m1受体拮抗剂
KR20220109401A (ko) * 2019-10-30 2022-08-04 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다진온
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
AU2021261383A1 (en) * 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US20230219942A1 (en) * 2020-06-09 2023-07-13 Relive Therapeutics Inc. Compounds comprising a three ring core as pd-1/pd-l1 blockers
AU2021302090B2 (en) * 2020-07-03 2024-01-18 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound and use thereof
WO2022111700A1 (zh) * 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
JP7623826B2 (ja) * 2020-12-18 2025-01-29 株式会社 資生堂 Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
CN116724044B (zh) * 2021-02-03 2025-10-31 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
TWI824403B (zh) * 2021-02-07 2023-12-01 大陸商武漢朗來科技發展有限公司 一種雜環化合物、其中間體、其製備方法及其應用
WO2022170974A1 (en) * 2021-02-09 2022-08-18 Jacobio Pharmaceuticals Co., Ltd. Tricyclic derivatives useful as parp7 inhibitors
WO2022177877A1 (en) 2021-02-16 2022-08-25 Ribon Therapeutics, Inc. Dosage regimens for parp7 inhibitors
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CA3212319A1 (en) * 2021-03-16 2022-09-22 Hualing XIAO Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof
JP7768592B2 (ja) * 2021-03-31 2025-11-12 デューク ストリート バイオ リミテッド 医薬化合物
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CA3217941A1 (en) * 2021-05-21 2022-11-24 Chengdu Baiyu Pharmaceutical Co., Ltd. Piperazine derivative and use thereof in medicine
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN117751108A (zh) * 2021-07-21 2024-03-22 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN117279907A (zh) * 2021-08-06 2023-12-22 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (zh) * 2021-08-16 2023-02-23 重庆华森制药股份有限公司 Parp7抑制剂及其应用
EP4387966A4 (en) * 2021-08-17 2026-02-11 Inventisbio Co Ltd PYRIDAZINONE OR PYRIDINONE COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CN116535395B (zh) * 2022-01-26 2024-07-09 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP7763538B2 (ja) * 2022-04-01 2025-11-04 諾沃斯達薬業（上海）有限公司 Ｐａｒｐ７阻害剤及びその使用
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
CN117586263A (zh) * 2022-08-09 2024-02-23 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
CN119584968A (zh) * 2022-08-09 2025-03-07 康百达（四川）生物医药科技有限公司 哌嗪类化合物在联合放疗治疗肿瘤中的用途
KR20250044423A (ko) * 2022-08-09 2025-03-31 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 피페라진 화합물과 pd-1 억제제 또는 pd-l1 억제제의 조성물 및 종양 치료에 있어서의 그의 용도
UY40397A (es) * 2022-08-17 2024-03-15 Jacobio Pharmaceuticals Co Ltd Formas sólidas del compuesto i o sales de las mismas
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
CN117551080A (zh) * 2022-11-11 2024-02-13 杭州师范大学 一种靶向降解parp7的protac化合物及其制备方法与应用
CN118027039A (zh) * 2022-11-14 2024-05-14 成都百裕制药股份有限公司 一种取代的哌嗪衍生物的晶体及其制备方法
GB202217888D0 (en) 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
WO2024146631A1 (zh) * 2023-01-06 2024-07-11 齐鲁制药有限公司 一种parp7抑制剂的制备方法
WO2024149234A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
WO2024149231A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2025036478A1 (zh) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的药物制剂、其制备方法及其用途
WO2025045134A1 (zh) * 2023-08-29 2025-03-06 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
TW202519233A (zh) * 2023-11-13 2025-05-16 大陸商康百達（四川）生物醫藥科技有限公司 一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157602C (zh) 1997-09-05 2004-07-14 松下电器产业株式会社 荧光偏振法检测样品的方法及其中使用的试剂
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
KR101286969B1 (ko) * 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
RS52626B (sr) 2006-07-25 2013-06-28 Cephalon Inc. Derivati piridizinona
MX2010005070A (es) * 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
RU2490260C2 (ru) * 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
CA2771190C (en) * 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) * 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
WO2019212946A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Screening methods for parp modulators
EA202092590A1 (ru) 2018-04-30 2021-04-08 Рибон Терапьютикс Инк. Пиридазиноны в качестве ингибиторов parp7
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
KR20220109401A (ko) 2019-10-30 2022-08-04 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다진온
US20240190844A1 (en) 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
MD3788040T2 (ro) 2023-10-31
JP6942896B2 (ja) 2021-09-29
IL278116B1 (en) 2023-12-01
EP3788040B1 (en) 2023-04-12
TWI811353B (zh) 2023-08-11
TW202344505A (zh) 2023-11-16
JP2021523104A (ja) 2021-09-02
PE20211382A1 (es) 2021-07-27
CR20200518A (es) 2021-03-22
KR20210014108A (ko) 2021-02-08
CA3098585A1 (en) 2019-11-07
SG11202010183XA (en) 2020-11-27
IL278116A (en) 2020-11-30
US20200123134A1 (en) 2020-04-23
CN112424188B (zh) 2025-06-27
EA202092590A1 (ru) 2021-04-08
CO2020013599A2 (es) 2020-12-21
FI3788040T3 (fi) 2023-06-13
ECSP20069404A (es) 2021-01-29
PL3788040T3 (pl) 2023-08-07
KR102862474B1 (ko) 2025-09-24
SMT202300172T1 (it) 2023-09-06
CN120987912A (zh) 2025-11-21
JP7518049B2 (ja) 2024-07-17
ZA202006549B (en) 2025-06-25
ES2949538T3 (es) 2023-09-29
US20250034120A1 (en) 2025-01-30
MX2023005804A (es) 2023-05-29
AU2019262927B2 (en) 2023-11-02
EP4234551A3 (en) 2023-10-11
CY1126132T1 (el) 2023-11-15
MA52486B1 (fr) 2023-04-28
LT3788040T (lt) 2023-06-26
PT3788040T (pt) 2023-07-12
MA52486A (fr) 2021-03-10
US11566020B1 (en) 2023-01-31
TW202014416A (zh) 2020-04-16
US10870641B2 (en) 2020-12-22
HRP20230458T1 (hr) 2023-07-21
IL308983A (en) 2024-01-01
PH12020551760A1 (en) 2021-06-28
RS64283B1 (sr) 2023-07-31
SI3788040T1 (sl) 2023-07-31
JP2022017221A (ja) 2022-01-25
US20190330194A1 (en) 2019-10-31
CN112424188A (zh) 2021-02-26
IL308983B2 (en) 2025-10-01
AU2024200566A1 (en) 2024-02-15
US10550105B2 (en) 2020-02-04
HUE062096T2 (hu) 2023-09-28
MX2020011465A (es) 2020-12-07
US20230192664A1 (en) 2023-06-22
BR112020022006A2 (pt) 2021-01-26
AU2024200566B2 (en) 2026-03-05
IL278116B2 (en) 2024-04-01
EP4234551A2 (en) 2023-08-30
US20210024502A1 (en) 2021-01-28
AR121419A1 (es) 2022-06-08
DK3788040T3 (da) 2023-05-08
WO2019212937A1 (en) 2019-11-07
TWI877697B (zh) 2025-03-21
IL308983B1 (en) 2025-06-01
US11014913B2 (en) 2021-05-25
EP3788040A1 (en) 2021-03-10
AU2019262927A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
BR112022001291A2 (pt) Amidas heterobicíclicas como inibidores de cd38
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CR20150578A (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CR20170500A (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
PH12017501879A1 (en) Methods for treating cancer
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CL2024001535A1 (es) Quinolinas y azaquinolinas como inhibidores de cd38
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
EA201492019A1 (ru) Способы лечения рака с помощью липопептидов